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Abstract
Nalmefene was the first treatment approved by the European Medicines Agency for reducing alcohol consumption
in adult patients with alcohol dependence. It is often presented as a paradigm shift in therapeutics, but major
issues limit the interpretation of the evidence supporting its use. The randomised trials submitted provided no
evidence of harm reduction, the differences on consumption outcomes were of questionable clinical relevance, the
target population was defined a posteriori and the drug was compared to a placebo although naltrexone was
already used off-label. No post-approval randomised study is currently designed to clearly address these issues. In
addition, nalmefene trials have been uncritically cited, even in guidelines. This experience reveals weaknesses in
drug evaluations in alcohol dependence, which call for changes. We propose to dispense with alcohol consumption
as a surrogate outcome, to consider comparative effectiveness issues, and to recommend randomised post-approval
studies in case of controversial approval.
On 13 December 2012, nalmefene, an opioid antagonist,
was approved by the European Medicines Agency (EMA)
for the reduction of alcohol consumption in adult patients
with alcohol dependence, a high drinking-risk level, no
physical withdrawal symptoms and not requiring immedi-
ate detoxification. It is the first treatment in this indication
when the usual aim in alcohol dependence is abstinence
from drinking. The approval [1] was based on the results
of two phase III randomised controlled trials (RCTs) last-
ing 6 months [2, 3], one lasting 1 year [4], and four earlier
RCTs including dose–response studies (two of these were
unpublished studies) [5, 6]. Some additional supporting
evidence was also presented, including pooled subgroup
analyses [7] and further analyses on the expected harm re-
duction (alcohol-related physical health outcomes, injuries
or social consequences) based on the literature data and
on modelling from the clinical trial data [8, 9]. Despite this
body of evidence, the approval was contested, with some
disagreement between and within the different health au-
thorities. For instance, six members of the Committee for
Medicinal Products for Human Use at the EMA expressed
divergent positions in an appendix to the assessment
report. The National Institute for Care and Excellence
(NICE) in the UK initially recommended nalmefene as
a possible treatment for alcohol dependence [10] but
subsequently distanced itself from this earlier advice [11].
The German and Swedish health authorities simply stated
that there was no added benefit from nalmefene [12, 13].
The RCTs performed have thus failed to demonstrate an
unequivocal benefit for the drug, despite the fact that, from
a regulatory perspective, this should be their principal aim.
We propose here to examine the evidence that led to the
approval of nalmefene and to understand why studies were
not unequivocal in this specific case, how their results were
integrated into the health authority decisions and how the
controversy spread in the medical literature. Our final pur-
pose is to propose relevant changes concerning therapeutic
evaluation in the field of alcohol dependence.
Search strategy and selection criteria
In this review of published and unpublished literature,
we looked for evidence, including clinical studies
(completed, terminated or ongoing), supportive stud-
ies (subgroup analyses and models) and commentaries
discussing the material used for the EMA approval
(letters and systematic or non-systematic reviews) about
the efficacy, effectiveness or efficiency of nalmefene,
via a search of PubMed, clinicaltrials.gov, isrctn.com,
clinicaltrialsregister.eu and lundbeck.com/trials, up to
and including 25 April 2016, using the term ‘nalmefene’. In
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addition, we used approval documents from the EMA, the
NICE, the French transparency committee, and a earlier
systematic review and meta-analysis by our team [14]. Ref-
erences were also identified by searching the bibliographies
of relevant publications. A flow diagram detailing this
process is presented in Fig. 1. All references are pro-
vided in Additional file 1.
Evidence of a small reduction in alcohol consumption
without any evidence of ‘harm reduction’
When the whole body of evidence derived from RCTs is
considered, no evidence is found in the meta-analyses
currently available to support the use of nalmefene for
harm reduction among people treated for alcohol de-
pendency [14]. Compared to a placebo, there were no
significant differences either on mortality or on quality
of life. Additionally, some crucial endpoints, such as ac-
cidents, injuries and somatic alcoholism complications,
were not directly measured as specific outcomes in the
trials, but were included in the composite outcome of
‘serious adverse events’, which were found to be similar
across groups (although there were more adverse events
in the nalmefene group). In its report, the EMA noted
that, from the available data, nalmefene does not appear
Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram detailing the study selection process. EMA European
Medicines Agency NICE National Institute for Health and Care Excellence
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to raise the incidence of accidents and falls in the target
population of alcohol-dependent patients [1]. However,
an approved treatment should aim to reduce accidents
and falls, rather than merely avoid increasing them.
When alcohol consumption outcomes were consid-
ered, there were significant reductions in heavy drinking
days and total alcohol consumption in the populations
studied. The evidence of the usefulness of nalmefene is
thus based on the assumption that reducing alcohol con-
sumption in alcohol-dependent patients will impact health
outcomes. While there is no high-quality randomized
evidence concerning the efficacy of managed alcohol
programmes on their own on these health outcomes [15],
some authors claim that this surrogate outcome is valid,
because it is assumed that reducing alcohol consumption
is useful in alcohol dependence. For example, numerous
epidemiological studies have suggested [16, 17] that high
consumption of alcohol is associated with an increased
risk for liver disease in comparison with lower consump-
tion. Therefore, it is tempting to assume that if individuals
reduce their consumption, they reduce their levels of risk
accordingly. But even if we consider that epidemiological
evidence is sufficiently plausible to legitimize a decrease in
consumption as a valid goal, it is not known what real
reductions, in term of quantity as well as in terms of
duration, might be associated with harm reduction. In
addition, the benefit of a given reduction could be very
different depending on the initial consumption level of
a given individual (the higher his or her consumption,
greater the benefit is expected to be) [18].
Furthermore, in the case of nalmefene, the reductions
observed in the consumption outcomes compared to
placebo were of questionable clinical significance (i.e. ef-
fect size of 0.2 for total alcohol consumption) [14], as
noted by the EMA report [1]. In addition, the fuzziness
surrounding the definition of these consumption out-
comes highlights another problem concerning nalmefene
trials. A recent paper suggested that the precise defin-
ition of the reductions in consumption (heavy drinking
days and total alcohol consumption) were added after
data collection ended [19].
An attrition bias cannot not be ruled out
Attrition is common in alcohol clinical trials and missing
data are an important methodological problem [20]. The
nalmefene trials were no exception. All three pivotal
studies had missing data for more than 35 % of the patients.
Missing data prevent good-quality intention-to-treat ana-
lyses, and can cause biased estimates of the treatment ef-
fect. Additionally, there were more withdrawals, including
more withdrawals for safety reasons, in the nalmefene
group than in the placebo group in the 6-month and 1-year
studies [14]. In addition to a possible unblinding of treat-
ment allocation, this exposes these studies to an attrition
bias. Additionally, the EMA noted that the differences in
treatment effect between nalmefene and placebo, and the
reduction in alcohol consumption in terms of reduction in
heavy drinking days and total alcohol consumption, were
inconsistent across the various sensitivity analyses [1].
No RCT performed in the target population
defined by the EMA
As stated in the EMA assessment report, because there
was a degree of uncertainty regarding the precise magni-
tude of the beneficial effects (or which analytical method
was best suited to measuring it) and its clinical relevance
in the total population, and in order to substantiate the
clinical efficacy and the clinical relevance of nalmefene
by defining a population where the benefit of nalmefene
would be greatest, subgroups analyses were performed a
posteriori [1]. These secondary analyses of the pivotal
studies included patients with a high or very high drink-
ing risk level (DRL) at baseline and who maintained a
high or very high DRL at randomisation in two [7] or
three [9] of the pivotal studies. Analyses from only two
studies were presented in the EMA report. This amounts
to <25 % of the existing randomised evidence, as shown
in Fig. 2, which presents the numbers of patients
Fig. 2 Number of patients enrolled in subgroup analyses in
comparison with all patients randomised to nalmefene or placebo
identified in a previous systematic review and meta-analysis [14]. Red
square represents all randomised patients. Orange square represents all
patients included in the three pivotal studies. Yellow square represents
the population indicated for the use of nalmefene in the three pivotal
studies. Light yellow square represents the population indicated for the
use of nalmefene in the two 6-month pivotal studies. The subgroup
analysis used for nalmefene approval was based on this population. * A
publication [7] reports 667 patients whereas another publication [9]
reports 641 patients for the two 6-month pivotal studies
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enrolled in these subgroup analyses in comparison with
all randomised patients in RCTs identified in a previous
meta-analysis [14]. Further to this, subgroup analyses are
generally considered explanatory rather than confirmatory,
especially when performed a posteriori [21, 22]. Because it
was a crucial point in the approval, the EMA mandated a
scientific advisory group to deal with this issue, and con-
cluded that while post hoc analyses were not ideal, they
were commonly used in clinical trials for psychiatric
drugs, given the high dropout rates encountered in these
populations [1]. The fact nevertheless remains that there
is no RCT performed in the specific population defined by
the EMA approval. In addition, it is not obvious that doc-
tors will be able to accurately select this target population
in a real-life setting [23]. Thus, the scientific advisory
group specifically advised that, to avoid misleading clini-
cians and to minimise off-label use, the therapeutic indica-
tions should clearly inform physicians (including general
practitioners) to enable them to readily recognise the pa-
tients who could be a target for the drug [1]. This issue is
central. The market of people who are continuing to drink
is potentially vast, especially as the drug is likely to be used
outside of the subgroup it has been recommended for
owing to difficulty in recognising this group and pressure
from patients and healthcare staff. For example, in France,
to ensure that the use defined by the approval will be
complied with as best as possible, the French transparency
committee required the prescription of the drug to be re-
stricted to specialists. Interestingly, the French minister of
health decided not to follow this advice and made possible
the prescription of the drug by general practitioners, argu-
ing that alcohol dependence is an important public health
issue [24].
Evidence for the effectiveness of the drug is
based on statistical models
When the subgroups were considered, even if differences
were found in terms of consumption outcomes [7] and
in terms of quality of life [25], there was still no evidence
of harm reduction. But a reduction in consumption evi-
denced in 6-month and 1-year studies seems highly unlikely
to be clinically relevant. The harm reduction approach is
based on models that are basically an extrapolation of the
results observed in subgroup analyses beyond the trial time
horizon [23]. This was therefore a very rash hypothesis.
The authors of these analyses conclude that the differences
between nalmefene and placebo on consumption outcomes
could reflect considerable effectiveness in terms of health
outcomes. There is no better example of this than their es-
timated reduction in all-cause mortality risk of 8 % (95 %
confidence interval 2–13 %) at 9 years [9]. This positive
outcome was calculated using data from the subgroup ana-
lyses of the pivotal studies combined with the risks for all-
cause mortality observed in meta-analyses in observational
studies that included people with alcohol dependence.
Other decision models using Markov chains compared
costs and effects of nalmefene over 5 years. These models,
also based on subgroups, supported the efficacy of nalme-
fene with substantial public health benefits [8], including a
reduction in productivity losses and crime events attribut-
able to alcohol [26]. They also suggested that it was a highly
cost-effective treatment option [27]. These models were
central to the EMA approval, because the scientific advisory
group focused on the model showing that even a moderate
decrease in drinking levels might be associated with a
decrease in both harmful events (e.g. mortality rates,
accidents) and in the relative risk of the medical outcomes
typically linked to excessive alcohol drinking (e.g. liver cir-
rhosis), before confirming that, however modest, the effect
size of nalmefene was clinically meaningful [1]. Neverthe-
less, these cost-effectiveness analyses were described by
another group as subject to considerable uncertainty,
particularly because they failed to address comparative
effectiveness issues, including comparison with appro-
priate psychosocial support and/or a relevant active
pharmacological comparator, such as naltrexone [11].
No RCT versus an active comparator
Nalmefene is a 6-methyl derivative of naltrexone [28].
The two compounds are both opioid antagonists and are
thus very similar [29]. But while naltrexone has long had
an approval in the indication ‘maintaining abstinence
after alcohol detoxification’, nalmefene was developed for
approval in the indication of ‘reducing alcohol consump-
tion’. Rather than evaluating an innovative compound,
the nalmefene phase III programme evaluated a rather
older option in a relatively new indication, while com-
parison with an active comparator was not warranted,
because there is no official comparator. This nonetheless
goes against clinical practice and beyond any pharmaco-
logical rationale. Naltrexone has been widely used off-
label in this indication and there has been evidence that it
is of interest for patients aiming to reduce heavy drinking
days [30]. Unsurprisingly, the estimated effect size for
naltrexone in this indication is small (~0.15–0.2), as is
the estimated effect size observed with nalmefene [14, 31].
Nevertheless, from an ethical perspective, there is the diffi-
cult question of whether a treatment that has some previ-
ous evidence for this use without having obtained approval
should be the comparator of choice.
Currently, the best available evidence for a difference
between the two compounds comes from indirect meta-
analyses. While the German Health authority criticised
analyses of this nature [13], a recent study compared
nalmefene and naltrexone indirectly and concluded that
nalmefene was superior, at least on outcomes related to
quantity of drinking [32]. However, in this study, sub-
group analyses on nalmefene RCTs were compared with
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naltrexone RCTs as a whole, resulting in a violation of
the similarity assumption that is necessary in indirect
meta-analyses [33]. Table 1 presents the results of this
analysis and results of an appropriate re-analysis where
no difference was found between the two drugs.
Post-approval evidence cannot address the critical
issues
One might expect that, even if the approval was contro-
versial, post-marketing data are necessary to confirm the
interest or otherwise of nalmefene. Among the six cur-
rently ongoing registered studies we have identified,
(1) two are RCTs versus placebo (NCT02752503 and
NCT02364947) but neither is performed in the target
population defined by the EMA; (2) two are non-
randomised studies (NCT02382276 is a continuation
study of NCT02364947, NCT02197598 being con-
ducted among cirrhotic patients), and (3) two are non-
randomised studies in ‘real-life’ European clinical settings
(NCT02492581, NCT02195817). Both are prospective co-
horts: the first was designed on request from the French
Transparency Commission and the second was imple-
mented in primary care but was terminated early as a
result of enrolment problems. Because of their non-
randomised design, these two studies will neither confirm
the efficacy of the drug in its target population, nor pro-
vide evidence of comparative effectiveness.
Dissemination of these issues in the literature
Even if these major limitations to the interpretation of
the trials have been raised by the different evaluations,
the nalmefene trials have been uncritically cited in the
subsequent literature. Among narrative reviews, 75 %
failed to present the topic as controversial (17 % allude
to it without any details and only 8 % present it as con-
troversial), and 54 % referred to the novelty of the drug
describing a ‘new’ [34] ‘approach’ [35] or ‘drug’ [36] or
‘target’ [37]. Some authors also refer to ‘a paradigm shift’
and a ‘historical step in the advancement of alcohol use
disorder treatment’ [38]. The 2015 Recommendations of
the French Alcohol Society, issued in partnership with
the European Federation of Addiction Societies, rec-
ommends nalmefene as the first-line medication for
reducing alcohol consumption in subjects with alcohol
dependence, without mentioning the subgroup of patients
defined by the EMA approval [39]. Links between authors,
Table 1 Direct (nalmefene versus placebo and naltrexone versus placebo) and indirect (nalmefene versus naltrexone) meta-analyses
concerning change from baseline in quantity of drinking
Studies Abstinence criterion Consumption criterion Soyka et al. analysis Analysis of complete data
Quantity of drinking Quantity of drinking
SMD [95 % CI] SMD [95 % CI]
CPH-101-0801a No more than 14 days At least 18 heavy drinking days in the last 12 weeks −0.48 [−0.87; −0.09] −0.21 [−0.46; 0.03]
ESENSE 1a [3] No more than 14 days At least 40 g alcohol/day for men and 20 g alcohol/day for
women and ≥6 heavy drinking days in the last 4 weeks
−0.46 [−0.74; −0.17] −0.35 [−0.56; −0.14]
ESENSE 2a [2] No more than 14 days At least 40 g alcohol/day for men and 20 g alcohol/day for
women and ≥6 heavy drinking days in the last 4 weeks
−0.25 [−0.52; 0.02] −0.15 [−0.34; 0.04]
SENSEa [4] No more than 14 days >6 heavy drinking days in the last 4 weeks −0.36 [−0.76; 0.03] −0.12 [−0.34; 0.1]
Nalmefene versus placebo, direct comparison, fixed-effect model −0.37 [−0.53; −0.21] −0.21 [−0.31; −0.10]
Anton (1999) [45] At least 5 days 5 or more drinks per day in the last 30 days −0.35 [−0.69; −0.01] −0.35 [−0.69; −0.01]
Balldin (2003) [46] No more than 14 days At least 20 heavy drinking days in the last 60 days 0.01 [−0.35; 0.37] 0.01 [−0.35; 0.37]
Anton (2005) [47] At least 5 days Average consumption of at least 5 standard drinks
per day for men and 4 for women in the past 90 days
−0.18 [−0.49; 0.13] −0.18 [−0.49; 0.13]
Kranzler (2000) [48] At least 3 days and no
longer than 28 days
Not specific 0.02 [−0.33; 0.37] 0.02 [−0.33; 0.37]
O’Malley (2008) [49] At least 4 days and no
more than 30 days
More than 14 drinks (women) or 21 drinks (men) per
week and at least 2 heavy drinking days during a
30-day period within the 90 days prior to baseline.
0.08 [−0.39; 0.55] 0.08 [−0.39; 0.55]
Naltrexone versus placebo, direct comparison, fixed-effect model −0.11 [−0.27; 0.05] −0.11 [−0.27; 0.05]
Nalmefene versus Naltrexone, indirect comparison, fixed-effect model −0.26 [−0.04; −0.49] −0.10 [−0.29; 0.10]
Heterogeneity in the network I2 = 0 %. Q = 5.9.
p = 0.65
I2 = 0 %. Q = 6.4.
p = 0.50
aFor those studies. Soyka et al. report results obtained in the subgroup analyses (patients concerned by the market approval) while this precaution was not taken
in the naltrexone trials. Results based upon this dataset are presented in the ‘Soyka et al. analysis’ column. Results based upon the complete nalmefene studies
are reported in the ‘Analysis of complete data’ columns
All analyses were performed using the frequentist approach, which is implemented in R in the netmeta library. Details about two important inclusion criteria of
the included studies (abstinence and previous consumption) are given to be informative about the similarity assumption that is necessary to interpret results of
indirect comparisons
Naudet et al. BMC Medicine  (2016) 14:119 Page 5 of 9
addiction societies and pharmaceutical companies have
been pointed to as an explanation for these uncritical
opinions [40]. While it seems impossible to determine
whether conflicting interests or strong allegiances
have distorted the interpretation of the evidence, a co-
authorship diagram illustrates the various links dis-
closed in the papers we have considered (Fig. 3). It
shows (1) a first cluster, with authors closely related to
the industry (as most were involved in the develop-
ment programme) who expressed positive views about
the drug; (2) a second cluster involving authors of
earlier studies, some of whom expressed some concern
about the usefulness of the drug (in the context of in-
terpretation of a negative study); and (3) a constella-
tion of small clusters or isolated authors including the
few contributions presenting the controversial issues
(mostly letters to editors), the authors of which rarely
disclosed conflicting interests.
Discussion
The key issue is whether nalmefene use is based on any-
thing more than a clever use of the data to get an existing
drug licensed for a new indication, or whether it is really a
new way of seeing things. Various authors seem enthusias-
tic about the concept of doing away with the need to aim
for abstinence from drinking, and proposing cutting down
consumption as being a valid goal. But even if this is genu-
inely a new paradigm in alcohol treatment, nalmefene was
evaluated using the traditional paradigm, and appears to
fall short of the evidence required. Indeed, the use of sur-
rogate outcomes, the questionable clinical relevance of the
differences evidenced, the use of a posteriori subgroup
analyses, and the inappropriate comparison with placebo
when another treatment was available are all reasons that
could explain why the results of nalmefene RCTs cannot
be interpreted as confirmatory. All of this leads to persist-
ent uncertainty, and to difficult and controversial decisions
for the health authorities, and is liable to generate another
public health problem, because care that is offered to pa-
tients is liable to be questioned and discredited.
In addition, and from a clinical perspective, marketing
a drug for people who continue to drink (especially if it
is ineffective) may have seriously detrimental psychological
and social implications. The licensing of nalmefene may
No COIs declared
COIs but not as an employee
Honoraria for at leat one paper
Worked for a company contracted by the industrialist
Worked for the industrialist
COIs not declared in the papers
Positive views about the drug
At least one allusion to a controversy in one paper
At least one paper describing a controversy
Fig. 3 Nalmefene co-authorship researcher networks. Each circle represents one author (larger diameter indicates a larger number of publication
by this author) and each line connecting two authors indicates the presence of at least one publication they have co-authored (larger diameter
indicates a larger number of publication in common). As indicated in the figure, the colours of the circles indicate conflict of interest (COIs)
declared in the considered papers, and the colour of the outline indicates the authors’ views about the drug. All analyses were performed
using the igraph library in R. All identified references were included excepted four references with no authors listed
Naudet et al. BMC Medicine  (2016) 14:119 Page 6 of 9
suggest to some people that they can continue drinking
when they might otherwise have come to the realisation
that they need to stop. Given that people with alcohol
problems are often in denial about the harmful effects of
drinking, and accustomed to looking for a chemical solu-
tion for their problems, this is a real danger that may actu-
ally perpetuate harmful drinking in the long term.
Therefore, scientists and clinicians need to engage in a
collaborative effort to reach an evidence-based consensus
that extends beyond the case of nalmefene and concerns
all regulation of medication for alcohol dependence. In
our opinion, this implies changes in our current research
paradigm. First, we propose doing away with alcohol
consumption as a surrogate for treatment success. We
propose instead the use of mortality and health outcomes
(motor vehicle crashes, injuries and harm). Alternatively,
quality of life could be considered, providing unambiguous
tools are developed to asses it in an optimal way [41]. Al-
though simple in appearance, these changes would be
revolutionary in the field of alcohol use disorders, where
very few trials have reported these health outcomes (or
when they have done so, they had not been designed
or powered to assess them correctly). A meta-analysis
including 22,803 participants concluded that the evi-
dence from trials was insufficient to draw any conclu-
sions about improved health outcomes attributable to
pharmacotherapy [42].
One can argue that adequately designed trials of health
outcomes would be unfeasible (too large and too long)
and that no company would agree to finance such trials.
Is it because such studies are genuinely not feasible?
One should bear in mind that ‘mega-trials’ have been
successful in the field of cardiovascular medicine. Or is
it because the current treatments will not show any
clinically relevant utility? Companies confident in their
products should have no reason to avoid the test of
mega-trial evidence [43]. Large, randomised, controlled
cluster trials may be of interest here, including studies
comparing different strategies such as abstinence and
harm reduction.
Second, we propose that the evaluation of therapies
should be collaborative and based on coherent agendas
where all compounds of interest are integrated into a
common research programme exploring issues of com-
parative effectiveness. In the current context of drug re-
search, where (1) trials are focused on single patented
compounds and designed to meet the requirements of the
regulatory bodies and (2) there is a strong competition be-
tween pharmaceutical companies, a change of this sort ap-
pears utopic. Thus we propose that health authorities
should be involved a priori in designing the studies that
can lead to market approval in order to ensure that com-
parative effectiveness issues are adequately addressed,
which is not the case currently, at least for the EMA [44].
Finally, we suggest that controversial approvals issued
on the grounds of subgroup analyses should be compul-
sorily confirmed in subsequent post-approval randomised
comparative studies. In case of negative results in such
studies, the drug approval should be withdrawn. In our
opinion, all these changes are necessary to avoid wastage
of resources, investments and scientific effort, and to put
an end to the persistent uncertainty that the case of
nalmefene exemplifies.
Obvious perspectives are (1) to explore the prevalence
of controversial approvals of the nalmefene type among
all EMA approvals and (2) with the help of economists,
to find alternative models where the requirement of
strong evidence will not lead to risk avoidance tactics by
those who evaluate the treatments.
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